Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

BACKGROUND: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban versus other oral anticoagulants in a large real-world popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Norby, Faye L., Bengtson, Lindsay G.S., Lutsey, Pamela L., Chen, Lin Y., MacLehose, Richard F., Chamberlain, Alanna M., Rapson, Ian, Alonso, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585896/
https://www.ncbi.nlm.nih.gov/pubmed/28874129
http://dx.doi.org/10.1186/s12872-017-0672-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585896/
https://www.ncbi.nlm.nih.gov/pubmed/28874129
http://dx.doi.org/10.1186/s12872-017-0672-5

Ejemplares similares